A total of 77% of the clinical cancer samples were involucrin positive, a much higher proportion than previously reported [23,24], possibly due to the increased sensitivity of RT-PCR in comparison with immunohistochemistry, although it remains a possibility that a subset of tumours expresses involucrin mRNA that is not translated. This evidence concerns the gene IVL and cancer.